Overview

Atazanavir and Endothelial Function in Older HIV Patients

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that older subjects with HIV randomly assigned to atazanavir will have increased bilirubin levels, reduced oxidative stress, and improved flow-mediated, endothelium-dependent vasodilation compared to subjects not switched to atazanavir.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Brigham and Women's Hospital
Treatments:
Atazanavir Sulfate